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Abstract
Background: A suggested role for T cells in COPD pathogenesis is based on associations between increased lung
cytotoxic T lymphocyte (CD8
+) numbers and airflow limitation. CD69 is an early T cell activation marker. Natural
Killer cell group 2 D (NKG2D) receptors are co-stimulatory molecules induced on CD8
+ T cells upon activation. The
activating function of NKG2 D is triggered by binding to MHC class 1 chain-related (MIC) molecules A and B,
expressed on surface of stressed epithelial cells. The aim of this study was to evaluate the expression of MIC A and
B in the bronchial epithelium and NKG2 D and CD69 on BAL lymphocytes in subjects with COPD, compared to
smokers with normal lung function and healthy never-smokers.
Methods: Bronchoscopy with airway lavages and endobronchial mucosal biopsy sampling was performed in 35
patients with COPD, 21 healthy never-smokers and 16 smokers with normal lung function. Biopsies were
immunohistochemically stained and BAL lymphocyte subsets were determined using flow cytometry.
Results: Epithelial CD3
+ lymphocytes in bronchial biopsies were increased in both smokers with normal lung
function and in COPD patients, compared to never-smokers. Epithelial CD8
+ lymphocyte numbers were higher in
the COPD group compared to never-smoking controls. Among gated CD3
+cells in BAL, the percentage of CD8
+
NKG2D
+ cells was enhanced in patients with COPD and smokers with normal lung function, compared to never-
smokers. The percentage of CD8
+ CD69
+ cells and cell surface expression of CD69 were enhanced in patients with
COPD and smokers with normal lung function, compared to never-smokers. No changes in the expression of MIC
A or MIC B in the airway epithelium could be detected between the groups, whereas significantly decreased
soluble MICB was detected in bronchial wash from smokers with normal lung function, compared to never-
smokers.
Conclusions: In COPD, we found increased numbers of cytotoxic T cells in both bronchial epithelium and airway
lumen. Further, the proportions of CD69- and NKG2D-expressing cytotoxic T cells in BAL fluid were enhanced in
both subjects with COPD and smokers with normal lung function and increased expression of CD69 was found on
CD8
+ cells, indicating the cigarette smoke exposure-induced expansion of activated cytotoxic T cells, which
potentially can respond to stressed epithelial cells.
Background
Chronic obstructive pulmonary disease, COPD, is char-
acterized by a progressive airway obstruction and
pulmonary inflammation. Studies have shown that
inflammation in COPD occurs in central and peripheral
airways as well as in the lung parenchyma [1,2].
Cigarette smoking is the major risk factor for the devel-
opment of COPD and cigarette smokers constitute over
90% of COPD patients in developed countries [3]. In
2030, the WHO has predicted COPD to be the third
leading cause of death worldwide. http://www.who.int.
However, the mechanisms by which cigarette smoke
induces COPD are still elusive.
The suggested role for T cells in the pathogenesis of
COPD is based on the associations between airflow
limitation and increased cytotoxic T lymphocytes (CD8
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increased CD8
+ T cell numbers have been found in the
airways of smokers in the early phase of COPD [5], as
well as in sputum, lung tissue and BAL fluid from
patients with established COPD [1,7,8]. The reason for
this increase is still not clear but viral infections [9] and
bacterial colonisation [10] have been suggested to pro-
voke the cytotoxic T cell responses.
We have previously reported increased numbers of
CD8
+ lymphocytes in the airway epithelium of subjects
with COPD compared to smokers with normal lung
function [11,12]. Moreover, compared to never-smokers,
the expansion and activation of airway CD8
+ lympho-
cytes, in terms of increased expression of CD69, HLA-
DR and CD25, have been demonstrated in smokers
without a clinical diagnosis of COPD (12). CD69 is an
early activation marker expressed on T, B and Natural
Killer (NK)-cells. CD69 is an inducible cell surface gly-
coprotein involved in lymphocyte proliferation and sig-
n a lt r a n s d u c t i o n[ 1 3 ] .O nt h eo t h e rh a n d ,H L A - D Ri sa
late activation marker, upregulated 48-60 hours after T
cells receptor (TCR) stimulation, and is regarded as a
more general marker of activated T-cells. High expres-
sion of CD25 is associated with the presence of regula-
tory T cells with down modulating action on
inflammatory reactions. Our previous data indicate that
cigarette smoke exposure per se would trigger the acti-
vation of CD8
+ T cells. A possible mechanism could be
induction of oxidative stress by components in the
tobacco smoke [12]. However, the expansion of acti-
vated cytotoxic T cells persisted in the airways of COPD
patients more than five years after smoking cessation
[12], suggesting a role for cytotoxic T cells also in estab-
lished COPD.
Epithelial cells undergoing stress are compromised in
function and are normally removed in order to control
inflammation and promote cellular repair. Multiple
mechanisms for the detection and elimination of
stressed cells have been described, including immune
cell activation[14]. As a consequence of tobacco smoke
exposure, injured or dead epithelial cells may be
increased due to epithelial injury combined with
impaired phagocytotic function [15]. A mechanism that
may provide a link between epithelial cell stress and
immune cell activation in the lungs involves the recog-
nition of stressed epithelial cells by the NK cell group 2
D (NKG2D) receptor. The NKG2 D receptors are con-
stitutively expressed almost exclusively on some cyto-
toxic T lymphocytes (NK cells, NK T cells and gδ
+ T
cells), whereas the NKG2 D receptor expression on CD8
+ T cells is induced upon activation [16]. The mechan-
ism by which the immune system recognizes injured or
stressed epithelial cells may represent a critical pathway
involved in tissue repair and remodeling processes
required for the preservation of pulmonary tissue and
the gas exchange function of the lung [17]. Recognition
of NKG2 D ligands by NKG2 D also appears to play a
role in the pathogenesis of diseases that are associated
with autoimmune conditions [16]. Lee et al have
suggested that emphysema is an autoimmune disease
characterized by correlation with anti-elastin antibody
and T-helper type 1 response, providing a putative link
of emphysema severity to adaptive immunity against
specific lung antigens [18].
Cytotoxic T cells can recognise stressed or infected
cells through the binding of NKG2 D to the MHC class
1 chain-related (MIC) molecules A and B, expressed on
the surface of the target cells [19]. Normally, MIC pro-
teins are constitutively expressed at a low degree on
lung epithelial cells and are upregulated upon cell acti-
vation or stress in smokers, possibly as a consequence
of oxidative stress [19]. Cell activation mediated by
NKG2 D binding to MIC induces proliferation, survival,
activation marker expression, cytokine production and
cytotoxicity in CD8
+ T cells, NK-cells and gδ
+ T cells
[20]. In CD8
+ T cells, NKG2 D is a potent co-stimula-
tory receptor to TCR-CD3 complex-dependent T cell
activation [21].
The importance of interactions between NKG2 D and
MIC molecules in COPD is not well understood.
However, Borchers et al have recently reported
NKG2D-mediated cytotoxic T cell activation in mice
after exposure to cigarette smoke [18]. NKG2 D ligand
over-expression induced emphysema in transgenic mice
and NKG2 D ligands were abnormally expressed in the
pulmonary epithelium of both animals exposed to cigar-
ette smoke and patients with COPD, implying a role in
the pathogenesis of COPD [19]. These authors also pos-
tulated that sustained expression of NKG2 D ligands
would lead to disruption of the alveolar architecture by
cytotoxic T lymphocyte-mediated apoptosis of pulmon-
ary epithelial cells. The aim of the present study was
therefore to further investigate the activation of cyto-
toxic T cells in stable COPD, as well as the importance
of the NKG2 D receptor and MIC ligands in smokers
and COPD patients.
Methods
Subjects
Seventy-two subjects participated in this study, 35
patients with moderate to severe COPD according to
GOLD-criteria (FEV1 35-80% of predicted), 21 healthy
volunteers with no smoking history (NS) and 16
smokers with normal lung function (S). Subject demo-
graphics are given in table 1. Of the COPD patients, 16
were current smokers and 19 were ex-smokers, with
smoking cessation more than five years prior to inclu-
sion. COPD subjects and smokers with normal lung
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(one pack year equals to 20 cigarettes/day). Current
smokers were not allowed to smoke for at least 12
hours prior to bronchoscopy. Both COPD-groups had
significantly reduced lung function described as FEV1/
FVC% ratio and FEV1% of predicted post-bronchodilata-
tion compared to both smokers with normal lung
function (p < 0.001 and p < 0.001) and never-smokers
(p < 0.001 and p < 0.001).
In a sub study, flow cytometry analyses were performed
in 9 patients with moderate to severe COPD, 9 healthy
volunteers with no smoking history (NS) and 14 smokers
with normal lung function (S). Of the COPD patients, 5
were current smokers and 4 were ex-smokers.
The COPD patients had received no treatment with
inhaled corticosteroids for at least four weeks prior to
the start of the study. Neither long-acting b2-agonists
nor long-acting anti-cholinergic drugs were allowed
within two weeks prior to bronchoscopy. Short-acting
b2-agonists and/or anti-cholinergic drugs were used on
demand. All the subjects were non-atopic and free from
symptomatic respiratory infection within a six week-
period prior to and during the study. They had no
history of chronic bronchitis or frequent exacerbations.
No anti-inflammatory drugs, such as non-steroidal anti-
inflammatory drugs or oral steroids or any additional
intake of vitamin C or E were allowed. Informed con-
sent was obtained from all volunteers after verbal and
written information and the study was approved by the
local Ethics Committee at Umeå University, Sweden,
and performed according to the declaration of Helsinki.
Methods
Spirometry
Dynamic spirometry variables (FVC and FEV1)w e r e
determined post bronchodilatation with 1 mg of terbu-
taline, using a Vitalograph spirometer (Vitalograph Ltd.
Buckingham, UK). At least three satisfactorily performed
and well-co-operated measurements were carried out,
according to the recommendations of the American
Thoracic Society [22].
Bronchoscopy
Atropine was given subcutaneously before bronchoscopy
and topical anaesthesia of the airways was obtained
using lidocaine. The subjects were examined in the
supine position using an Olympus BF IT160 video
bronchoscope (Olympus, Tokyo, Japan). Bronchial wash
(BW) was performed by infusing two aliquots of 20 ml
of sterile sodium chloride (NaCl), pH 7.3 at 37°C that
were gently sucked back after each infusion and pooled
into a tube placed in iced water. Bronchoalveolar lavage
(BAL) was performed by infusing three aliquots of 60
ml of sterile sodium chloride (NaCl) in either the middle
or lingula lobe. Four to six endobronchial mucosal biop-
sies were collected, from the proximal airway carinae of
the contra-lateral lung. Endobronchial biopsies and
recovered fluids were immediately transported to the
laboratory for analysis.
Processing and staining of bronchial biopsies
The endobronchial mucosal biopsies were immediately
fixed in ice cold acetone with the inclusion of the pro-
tease inhibitors phenylmethylsulphonyl fluoride (2 mM)
and iodoacetamine (20 mM). The biopsies were subse-
quently processed into glycol methacrylate (GMA) resin
according to a previously described protocol [23]. The
GMA blocks were stored in air tight containers at -20°C
until the staining procedure was initiated. In order to
detect mucus secreting cells (goblet cells) in the epithe-
lium, two sections from each subject were stained with
Alcian blue. Immunohistochemical staining with mono-
clonal antibodies (MoAbs) against CD3, CD4, CD8
(DAKO, Glostrup, Denmark), NKG2 D, MICB (R & D,
A b i n g d o n ,U K ) ,a n dap o l y c l o n a la n t i b o d ya g a i n s t
MICA (R & D, Abingdon, UK) was performed as
described in detail elsewhere [24]. Briefly, 2-μm sections
were treated to inhibit endogenous peroxidases by
a p p l y i n gas o l u t i o no f0 . 3 %h y d r o g e np e r o x i d ei n0 . 1 %
sodium azide. Additionally, no n - s p e c i f i ca n t i b o d yb i n d -
ing was blocked by the use of Dulbecco’s minimal
essential medium containing 10% foetal calf serum and
1% bovine serum albumin. Undiluted blocking medium
was applied for 30 minutes and then poured off, where-
upon mouse MoAbs and goat polyclonal antibodies
were applied and incubated for 16-20 h at room tem-
perature. Biotinylated rabbit anti-mouse immunoglobu-
lin F(ab’)2 (Dako, Glostrup, Denmark) or swine anti-goat
immunoglobulin was added to each section and incu-
bated for 2 h, and subsequently a complex of streptavi-
din-biotin-horseradish and peroxidase (Dako) was added
for 2 h. After rinsing in TBS, aminoethyl carbazole
(AEC) in distilled water and hydrogen peroxide were
Table 1 Demographics and spirometry values
Never-
smokers
n=2 1
Smokers
n=1 6
COPD
Ex-smokers
n=1 9
COPD
Smokers
n=1 6
Male:Female 11:10 7:9 13:6 4:12
Age 66 ± 5.2 61 ± 6.8 68 ± 5.8 64 ± 5.5
Smoking(pack
years)
0 (0-0) 31 (21-42) 35 (18-42) 29 (24-48)
COPD stage
# NA NA 2 and 3 2 and 3
FEV1/FVC % 78 (76-82) 79 (77-83) 55 (49-64)* 60 (57-63)*
FEV1 %o f
predicted
101 (90-116) 110 (99-119) 46 (36-53)* 54 (39-68)*
Data are shown as mean±standard deviation for age, median and inter quartile
range for all others. FEV1: Forced expiratory volume in one second, measured
post bronchodilatation; FVC: Forced vital capacity. # according to GOLD
standard [3]. NA: not available. *indicate significant difference compared to
smokers with normal lung function and never-smokers (p < 0.001).
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positive immunoreactions. 3.3-diaminobenzidine (DAB)
diluted in distilled water and hydrogen peroxide induced
a brown colour for positive immunoreactions. All
sections were counterstained with Mayer’s haematoxylin.
Primary antibody was omitted on sections serving as
negative controls. Two stained sections from each parti-
cipant were estimated with respect to epithelium quality,
and the best of these was used for quantifying positively
stained epithelial cells.
Quantification of staining in mucosal biopsy specimens
The epithelium was defined as the intact area above the
basement membrane. The total length was calculated by
use of computer assisted image analysis (Qwin, Leica
Q500IW; Leica, Cambridge, UK). Quantification of posi-
tively stained cells was performed using a light micro-
scope. The number of positively stained cells was
expressed as cells per millimeter of epithelium as, pre-
viously described [24]. Quantification of MIC antigens
in the bronchial epithelium was performed on sections
developed with DAB as the substrate. The epithelium
expression was quantified and expressed as the percen-
tage of epithelial area with positive immunostaining as
compared with the total epithelial area. Quantification
of NKG2 D antigens was performed on sections devel-
oped with AEC as the substrate.
Positive staining for CD3
+,C D 4
+ and CD8
+ lympho-
cytes revealed a ring staining pattern (figure 1).
Cell preparation and MIC analyses
The chilled bronchial wash (BW) and bronchoalveolar
lavage (BAL) were processed by filtrated through a
nylon filter (pore diameter 100 μm, Syntab Product AB,
Malmö, Sweden) and centrifuged (400 g, 15 minutes, at
4°C). The cell pellet was resuspended in PBS. The total
number of cells was counted and adjusted to a final
concentration of 10
6 cells/ml.
Cytocentrifuged specimens with 50 μl suspended cells,
from 10
6/ml, were prepared using a Cytospin 2® at 450
rpm for 5 minutes (Shandon Southern Instruments Inc.,
Sewikly, PA, USA). Slides were stained according to
May-Grünwald Giemsa and 500 cells per slide were
counted for standard cell differential counts.
The measurement of soluble MICA and MICB in BAL
and BW supernatant was performed by commercially
available Elisa kits, (R & D Systems, Abingdon United
Kingdom.).
Flow cytometry analysis
Lymphocyte subsets in BAL were determined by flow
cytometry. BAL cells were centrifuged and diluted to a
final concentration of 10
6 cells/ml. For each test, 10 μl
of antibody solution was added to 200 μl of cell suspen-
sion and allowed to bind for 30 minutes at 4°C in dark-
ness. Red blood cells were lysed with 2 ml FACS™Lysing
solution (Becton Dickinson Immunocytometry Systems,
San Jose, CA, USA) for 10 minutes at room temperature
and the remaining cells were washed by adding PBS to
the tubes and centrifuged at 4°C for 10 minutes, 300 g.
This washing procedure was performed twice. Cells
were then fixed with 500 μlC e l l F I X ™(Becton Dickinson
Immunocytometry Systems, San Jose, CA, USA) before
analysis using a FACScan™(Becton Dickinson) flow
cytometer. Up to 10,000 total events were collected per
sample. The lymphocyte population was gated based on
their physical characteristics in a region, according to
their characteristic forward scatter (FCS) and side scat-
ter (SSC) profiles. To obtain CD3
+,C D 8
+ and NKG2D
+
cells, the cells were stained with peridinin chlorophyll
protein complex (PerCP) conjugated anti-human CD3,
Figure 1 Immunohistochemistry staining of serial sections for CD3 and CD8. The arrows indicate positive cell staining.
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human CD8 and phycoerytrin (PE) conjugated anti-
h u m a nN K G 2Di nt h es a m et e s tt u b e .T h ep e r c e n t a g e
of different cell types was counted out of gated CD3
+
lymphocytes. Source of antibodies for flow cytometry
was Becton Dickinson Immunocytometry Systems, San
Jose, CA, USA, except for NKG2 D which was provided
by R & D, Abingdon, UK.
Statistical analysis
Flow cytometry data were acquired and analysed using
CellQuest Software (Becton Dickinson, San Jose, CA,
USA). Statistical comparisons between the three groups
were carried out using Kruskal-Wallis test and a p-value
of less than 0.05 was considered significant. If the Krus-
kal-Wallis test indicated significance, the Mann-Whitney
U-test was used for post-hoc analysis for comparison
between two groups, with corrections of p-values
according to Bonferroni (a p-value less than 0.017 was
considered significant). In order to distinguish between
COPD and smoking-related effects, a subgroup analysis
was carried out within the COPD group. The ex-smok-
ing COPD group was compared to both the smoking
COPD group and the never smoking group, using
Mann-Whitney U-test. Here, a p-value of less than 0.05
was considered significant.
Results
Immunohistochemistry analysis of endobronchial mucosal
biopsies
The number of epithelial CD3
+ lymphocytes was
increased in both smokers with normal lung function
(3.00; 1.27-7.48 cells/mm
2) (median; inter quartile
range) and in the COPD group (3.14; 0.76-7.94), com-
pared to never-smokers (0.65; 0.00-2.22) (p = 0.006 and
p = 0.005 respectively), (figure 2). Epithelial CD3
+ lym-
phocyte numbers were similar in COPD subjects and in
smokers with normal lung function. Epithelial CD8
+
lymphocyte numbers were higher in the COPD group
(2.72; 0.00-5.69, p = 0.001) compared to the never-
smoking controls (0; 0.99-2.01), but without a significant
difference compared to smokers with normal lung func-
tion (1.34; 0.00-4.71). There was no difference in epithe-
lial CD4
+ cells or MICA expression between the three
groups, (figure 3 and 4). Neither MICB nor NKG2 D
expression was detectable in bronchial tissue. Tonsil tis-
sue acted as positive control for the MICB and NKG2 D
stainings.
Differential cell counts in BALF
Smokers with normal lung function had increased num-
ber of total leukocytes in BALF compared to never-
smokers (p < 0.001), whereas a non significant increase
was noted compared to subjects with COPD (p = 0.03).
Among leukocytes, the number of macrophages was
increased in smokers with normal lung function com-
pared to never smokers (p < 0.001) with a trend towards
as i g n i f i c a n ti n c r e a s ec o m p a r e dt oC O P Ds u b j e c t s
(p = 0.02) (table 2). In smokers with normal lung function,
the numbers of neutrophils were increased compared to
never smokers (p = 0.007), whereas mast cell numbers
were increased compared to COPD subjects (p = 0.003).
T oe x a m i n ew h e t h e rt h ed i f f e r e n c ei na i r w a yi n f l a m -
mation between COPD patients and smokers with nor-
mal lung function was due to smoking habits, the
COPD patients were divided into current smokers and
ex-smokers. The results of this subgroup analysis
showed that smoking COPD patients had increased
numbers of BAL macrophages (p < 0.001) compared to
ex-smoking COPD patients (table 2).
Analysis of T cells subpopulations in BALF
The percentage of CD8
+ NKG2D
+ cells among gated
CD3
+cells was enhanced in patients with COPD and
smokers with normal lung function, compared to never-
smokers (p = 0.001 and p = 0.002 respectively). The per-
centage of CD8
+CD69
+ cells among gated CD3
+cells was
enhanced in patients with COPD and smokers with
normal lung function compared to never-smokers
(p = 0.012 and p = 0.001 respectively). Also, CD69 med-
ian fluorescence intensity was increased on CD8
+ T
cells in COPD subjects and smokers with normal
lung function compared to never-smokers (p = 0.007
and p = 0.001 respectively) (figure 5). There were no
differences in median fluorescence intensity in NKG2 D
or HLA-DR on CD8
+ T cells.
Analysis of soluble MIC
Soluble MICB (sMICB) was undetectable in BW from
smokers with normal lung function, whereas in never-
smokers sMICB was detectable (83; 0.0-269 pg/ml,
p = 0.002) (figure 6).
MICA was not detectable in either BW or BAL.
Discussion
We have demonstrated increased numbers of CD8
+ T
cells in the bronchial epithelium of subjects with COPD.
These data are in concordance with previous studies of T
cells in the bronchial epithelium and BALF from COPD
patients performed by us and others [5,7,8,11,12]. In
addition, we now report that the cytotoxic T cells in
BALF of smokers with normal lung function and COPD
patients express high levels of the co-stimulatory receptor
NKG2 D and the early cell activation marker CD69.
These data imply that cytotoxic T cells recruited to the
airways of both COPD subjects and smokers without
clinical symptoms of COPD are highly activated and can
respond to stressed and injured epithelial cells.
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+ T cells is to recognize
and kill cells expressing ligands stimulating cytotoxicity.
They kill target cells by inducing apoptosis through
secretion of perforin, granzyme, and by Fas/Fas ligand
(FasL) interactions. An inverse relationship is reported
between CD8
+ T lymphocytes and lung function in
COPD [5] and that the extent of lung emphysema is
associated with the number of T lymphocytes in lung
parenchyma [25]. Further, several studies have shown
that the numbers of CD8
+ T lymphocytes are increased
in central and peripheral airways, also in emphysema-
tous subjects [2,5,26,27]. Altogether, these findings sup-
port a role for cytotoxic T cells in the development of
lung emphysema and COPD. Morissette et al did
reported, however, no difference in expression of
perforin, granzyme B and FasL of CD8
+ T lymphocytes
in peripheral blood in emphysematous subjects [28],
supporting the notion that CD8
+ T cells are not acti-
vated in the circulation of smokers and subjects with
COPD. Despite data on increased T lymphocytes in
emphysema and COPD, few studies have described their
state of activation or function. It has been hypothesized
that COPD have an autoimmune component [29] and
Lee et al have reported that emphysema is characterized
by an association of antielastin antibody and T helper 1
response [18]. In the present study we were not able to
support a specific autoimmune component in COPD,
since no differences were observed in the studied
immune cell populations between COPD patients and
smokers without clinical disease.
Figure 2 Immunohistochemistry analysis of bronchial epithelium in never-smokers (NS), smokers with normal lung function (S), and
COPD subjects (a and b). COPD subjects are further divided into ex-smokers (ex-s) and smokers (s) (c and d). CD3 and CD8 are given as
number of cells per mm epithelium. Significance levels are noted as ** p < 0.01, *** p < 0.001. Data are given as median and IQR.
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Page 6 of 11Figure 3 Immunohistochemistry analysis of MIC A (a) and negative control (b). Positively stained cells are indicated by the brown colour
(DAB).
Figure 4 The expression of MICA in epithelium of never-smokers (NS), smokers with normal lung function (S) and COPD.V a l u e sa r e
given in percent positive staining in bronchial epithelium. Among the COPD group (black circle) indicates ex-smokers, whilst (white triangle)
indicates smokers. Data are given as median and IQR
Table 2 Differential cell counts of white blood cells in BAL fluid, given in number cells/ml*10
4.
Never smokers
(NS)
n=2 1
Smokers
(S)
n=1 6
COPD
n=3 3
p COPD
ex-smokers
n=1 9
COPD
smokers
n=1 4
p
Total
leukocytes
19 (13-27) 40 (31-50) 25 (17-30) P < 0.001 NS vs S P = 0.03
S vs COPD
18 (15-26) 29 (25-45) P = 0.02 COPD ex-svs
COPD s
Macrophages 16 (11-22) 37 (29-47) 22 (14-28) P < 0.001 NS vs SP = 0.02
S vs COPD
15 (11-21) 27 (24-40) P < 0.001 COPD ex-svs
COPD s
Neutrophils 0.17 (0.08-0.29) 0.47
(0.24-0.98)
0.26
(0.06-0.5)
P = 0.007 NS vs S 0.28
(0.07-0.6)
0.19
(0.06-0.5)
NS
Lymphocytes 1.7 (0.9-2.7) 2.3 (1.4-3.6) 1.4
(0.90-3.0)
NS 2.0 (1.1-3.3) 1.3
(0.58-1.9)
NS
Eosinophils 0.06 (0-0.16) 0.05 (0-0.23) 0.12
(0.03-0.46)
NS 0.05
(0.01-0.35)
0.21
(0.05-0.62)
NS
Mast cells 0.01 (0.0-0.03) 0.03
(0.005-0.04)
0.0
(0.0-0.01)
P = 0.003 S vs COPD 0.005
(0.00-0.01)
0.0
(0.0-0.008)
NS
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+CD69
+ cells and the increased expression of the cell
surface receptor CD69 on CD8
+ T cells in both COPD
and smokers with normal lung function, compared to
never-smokers. This finding is in line with our pre-
viously published data, supporting the hypothesis that
CD8
+ T cells are highly activated in COPD but also in
smokers without clinical symptoms of COPD [12].
CD69 is a constitutively expressed early activation
marker and acts as a co-stimulatory molecule for T cell
activation and proliferation, within one or two hours
after TCR engagement [13]. It has also been shown that
expression of CD69 is higher on sputum -lymphocytes
than on peripheral blood cells [30]. The precise role for
CD69 in immunity has not been elucidated owing to the
absence of a known ligand and adequate in vivo models
to study its physiological function [31]. In contrast to
the data presented in this study, we previously reported
Figure 5 Flow cytometry analyses of BAL T cells in never-smokers (NS), smokers with normal lung function (S) and COPD.D a t aa r e
given as percent and median fluorescent intensity (MFI) of gated CD3
+ cells. Within the COPD group, ex-smokers (black circle) and current
smokers (white triangle) are indicated. A p-value below 0.017 is considered significant. Significance levels are noted as * p < 0.017, ** p < 0.01,
*** p < 0.001. Data are given as median and IQR.
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+ cells in BALF
[12]. The divergent results are due to differential gating
procedures when performing analysis of flow cytometry
data, i.e. in this study cytotoxic T cells were identified
by using both anti-CD3 and anti-CD8 antibodies, while
in the previous study only anti-CD8 antibodies were
used to define the cytotoxic cells. Therefore, it is likely
that the observed increase of HLA-DR in COPD and
smokers with normal lung function was related to non-
T cells with CD8 expression, such as small mast cells,
macrophages or dendritic cells.
The NKG2 D ligands, MICA and B, are stress-induci-
ble and primarily expressed on epithelial cells [32]. In
spite of the large numbers of subjects included in the
present study, we did not find any statistical difference
w h e ni tc o m e st ot h eN K G 2Dl i g a n dM I C Ai nt h e
bronchial epithelium. We hypothesize that the bronchial
epithelium is not activated in terms of MICA or MICB,
in our subjects with stable COPD. So far, only one pub-
lished study has investigated the NKG2 D receptor and
MIC ligands in COPD. In endobronchial biopsies and
peripheral lung resection tissue from patients with lung
cancer, Borchers et al found significantly increased
expression of MICA in current smokers with COPD,
compared to never smokers and former smokers with
C O P D .I nt h a ts t u d y ,h o w e v e r ,t h eC O P Dp a t i e n t sa l s o
suffered from lung cancer, which hypothetically may
have influenced the MIC A expression, as NKG2D/
NKG2 D ligand interactions also play a role in immune
recognition of tumors [33]. The discordant result can
also be due to differences in subjects medication, since
inhaled steroid treatment was given to the patients in
the study by Borchers. In our study, the subjects
received no treatment with inhaled corticosteroids dur-
ing at least four weeks prior to study start. Neither
long-acting b2-agonists nor long-acting anti-cholinergic
drugs were allowed within two weeks prior to broncho-
scopy. All patients included in our study were in stable
state of COPD, i.e. without any infectious exacerbations.
We did not detect an upregulation of MICA in bron-
chial biopsies from smokers or COPD subjects, and MICB
was undetectable in all samples. Since the MIC proteins
can be shedded from the epithelial cells into the alveolar
space, we also analysed soluble MIC (sMIC) released to
bronchial wash and BAL fluid. We observed that sMICB
was decreased or undetectable in BW of smokers with
normal lung function and nearly all subjects with COPD,
when compared to never-smokers. This observation might
be explained by adsorption of MICB by the large number
of NKG2D-expressing cells in the airways of these indivi-
duals, or alternatively by the interference of cigarette
smoking on the detection of sMICB in BW.
It should, however, be noted that there were no statis-
tically significant increase in total lymphocyte numbers
in our group of COPD patients, only the distribution of
T cell subsets within the lymphocyte population was
changed. It was also evident that subjects with stable
COPD, did not display any increase in neutrophils or
macrophages in BAL fluid. When sub-dividing the
patients in current smoking and non-smoking, it was
clearly demonstrated that expansion of macrophages in
airways was associated with smoking rather than COPD,
confirming our previously published data [12]. This is
consistent with a primary role of macrophages in
inflammatory responses to noxious particles and gases,
e.g. components in tobacco smoke.
Conclusions
In summary, we demonstrated an increased numbers of
cytotoxic T cells in COPD, in both bronchial epithelium
Figure 6 Analysis of sMICB in bronchial wash (BW) of never-smokers (NS), smokers with normal lung function (S) and COPD by ELISA.
Values are given as pg/ml. Within the COPD group, ex-smokers (black circle) and current smokers (white triangle) are indicated. A p-value below
0.017 is considered significant. Significance levels are noted as ** p < 0.01. Data are given as median and IQR
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Page 9 of 11and airway lumen. CD69- and NKG2D-expressing T
cells in BAL fluid were enhanced in both subjects with
COPD and smokers with normal lung function, indicat-
ing that cigarette smoke exposure triggers the expansion
of activated cytotoxic T cells, possibly by responding to
injured epithelial cells. The cytotoxic T cells remained
activated years after smoke cessation of COPD patients,
implicating a role of these in the chronicity of COPD.
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